112 related articles for article (PubMed ID: 21674478)
1. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells.
Benhamron S; Tirosh B
Eur J Immunol; 2011 Aug; 41(8):2390-6. PubMed ID: 21674478
[TBL] [Abstract][Full Text] [Related]
2. TSC1 Promotes B Cell Maturation but Is Dispensable for Germinal Center Formation.
Ci X; Kuraoka M; Wang H; Carico Z; Hopper K; Shin J; Deng X; Qiu Y; Unniraman S; Kelsoe G; Zhong XP
PLoS One; 2015; 10(5):e0127527. PubMed ID: 26000908
[TBL] [Abstract][Full Text] [Related]
3. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
4. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
[TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli.
Donahue AC; Fruman DA
Eur J Immunol; 2007 Oct; 37(10):2923-36. PubMed ID: 17724683
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 activation in B cells confers impairment of marginal zone microarchitecture by exaggerating cathepsin activity.
Meena NK; Pattanayak SP; Ben-Nun Y; Benhamron S; Kumar S; Merquiol E; Hövelmeyer N; Blum G; Tirosh B
Immunology; 2018 Dec; 155(4):505-518. PubMed ID: 30144045
[TBL] [Abstract][Full Text] [Related]
7. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
[TBL] [Abstract][Full Text] [Related]
8. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.
Ghosh S; Tergaonkar V; Rothlin CV; Correa RG; Bottero V; Bist P; Verma IM; Hunter T
Cancer Cell; 2006 Sep; 10(3):215-26. PubMed ID: 16959613
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E
Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738
[TBL] [Abstract][Full Text] [Related]
10. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
11. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.
Chen W; Ma T; Shen XN; Xia XF; Xu GD; Bai XL; Liang TB
Cancer Res; 2012 Mar; 72(6):1363-72. PubMed ID: 22287548
[TBL] [Abstract][Full Text] [Related]
14. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells.
Ndong M; Kazami M; Suzuki T; Uehara M; Katsumata S; Inoue H; Kobayashi K; Tadokoro T; Suzuki K; Yamamoto Y
Nutr Res; 2009 Sep; 29(9):640-7. PubMed ID: 19854379
[TBL] [Abstract][Full Text] [Related]
15. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.
Jiang X; Yeung RS
Cancer Res; 2006 May; 66(10):5258-69. PubMed ID: 16707451
[TBL] [Abstract][Full Text] [Related]
16. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex 1-mechanistic target of rapamycin complex 1 signaling determines brown-to-white adipocyte phenotypic switch.
Xiang X; Lan H; Tang H; Yuan F; Xu Y; Zhao J; Li Y; Zhang W
Diabetes; 2015 Feb; 64(2):519-28. PubMed ID: 25213336
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
19. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
20. Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.
Ding L; Han L; Li Y; Zhao J; He P; Zhang W
Neoplasia; 2014 Nov; 16(11):909-17. PubMed ID: 25425965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
